Pure Global

Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) - Trial NCT06274801

Access comprehensive clinical trial information for NCT06274801 through Pure Global AI's free database. This Phase 3 trial is sponsored by GB002, Inc. and is currently Not yet recruiting. The study focuses on Pulmonary Arterial Hypertension. Target enrollment is 300 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06274801
Phase 3
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06274801
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arterial Hypertension (PAH)

Study Focus

Seralutinib

Interventional

drug

Sponsor & Location

GB002, Inc.

Gossamer Bio Inc.

Kansas City,Richmond, United States of America

Timeline & Enrollment

Phase 3

Jun 01, 2024

Dec 01, 2026

300 participants

Primary Outcome

Incidence of treatment-emergent adverse events (TEAEs)

Summary

This open-label extension study will evaluate the long-term safety, tolerability and efficacy
 of orally inhaled seralutinib in subjects who have completed a previous seralutinib study

ICD-10 Classifications

Primary pulmonary hypertension
Other secondary pulmonary hypertension
Pulmonary heart disease and diseases of pulmonary circulation
Stenosis of pulmonary artery
Pulmonary heart disease, unspecified

Data Source

ClinicalTrials.gov

NCT06274801

Non-Device Trial